language flag

English

  • language flag

    English

  • language flag

    German

  • language flag

    Italian

  • language flag

    Spanish

Therakos Logo - Dark
Languages:
Therakos e-learning platform
  1. Home
  2. Therakos Institute
  3. Centres of Excellence
  4. A–Z of Treating Patients with ECP – The Nordic Approach

A–Z of Treating Patients with ECP – The Nordic Approach (1)

30 - 31 October 2023

Location

The Oslo University Hospital, Oslo, Norway

The Oslo University Hospital, Oslo, Norway

More about the Centre

The Goal

The goal of the practical course is to share the experience on how to successfully set up a new ECP centre and to optimise patient management. The interactive setting fosters discussion between peers.

Agenda

Download Agenda PDF

Day 1 - 30 October 2023

Arrival of participants

 

20.00 – 20.15
Meeting at hotel lobby

 

20.15
Dinner with the faculty

Day 2 - 31 October 2023

 

09.00 – 09.30
ECP treatment pathway – a patient perspective - Patient

 

09.30 – 10.15
Department and ECP set-up - Jørn Kristiansen, Nurse

 

10.15 – 11.00
Vascular access - Daniel Wergeland, Nurse

 

11.00 – 11.15
Group discussion

 

11.15 – 11.30
Coffee break

 

11.30 – 12.15
Patient focus and Nordic guidelines on ECP - Alba Pons, RN ECP Nurse

 

12.15 – 13.00
ECP in acute and chronic GvHD – the Oslo experience - Alba Pons, RN ECP Nurse

 

13.00 – 13.45
Impact of ECP treatment on Quality of Life (QoL) - Camilla Skovlund, Nurse

 

13.45 – 14.15
Health economic parameters in GvHD – a local assessment - Alba Pons, RN ECP Nurse

 

14.15 – 15.15
Lunch

 

15.15 – 15.45
Managing patients – a cross-departmental approach - Jørn Kristiansen, Nurse

 

15.45 – 16.15 
Nurses role in ECP treatment - Mario Galluzzi, Nurse

 

16.15 – 16.45
Group discussion

 

16.45 – 17.00
Final remarks and close - Alba Pons, RN ECP Nurse

 

ECP: Extracorporeal Photopheresis, GvHD: Graft versus Host Disease

 

All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

This information is not intended for healthcare professionals based in the US and Canada.

Hosted by

Alba Pons
Alba Pons

RN ECP Nurse Rikshospitalet, Oslo University Hospital

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

Our Centres of Excellence (CoE) Programme is for customers only. If you are interested in attending our CoE courses please contact your Sales Representative.

Explore related courses

Sep 28 - 29, 2023

THERAKOS CELLEX Photopheresis System Practical Course

The Tirol Kliniken, Innsbruck, Austria

Find out more

Nov 30 - Dec 1, 2023

THERAKOS CELLEX Photopheresis System Practical Course 

The Tirol Kliniken, Innsbruck, Austria

Find out more

You are leaving the THERAKOS.EU website.
Therakos does not review or control the content of non-Therakos websites, and this hyperlink does not constitute an endorsement by Therakos of the site’s content. Therakos privacy procedures do not apply to the owners of a non-Therakos website.

Important Safety Information
For the TherakosTM Photopheresis
Procedure

Indications

The THERAKOSTM CELLEXTM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOSTM Photopheresis is contraindicated in:

  • Patients possessing a specific history of a light sensitive disease.
  • Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm3.
  • Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOSTM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

  • Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
  • Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
  • When prescribing and administering THERAKOSTM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

  • Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
  • Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
  • Treatment frequency exceeding labelling recommendations may result in anaemia.
  • Venous access carries a small risk of infection and pain.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

  • Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
  • Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
  • Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
  • Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

  • Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
  • Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
  • Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
  • Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.

This website is not intended for healthcare professionals based in US, France and Canada.

Please verify your status below.

I am a healthcare professional and

I am eligible to access this part of the website

I am not a healthcare professional.

I would like to return to the homepage

This website is not intended for residents
based in the US, France or Canada.

PLEASE CLICK HERE TO ENTER

If you are a French resident, please visit www.therakos.fr

Applications for the 2022 EIA are now closed.
The 2022 ECP Immunomodulation Investigator Award has been awarded to Professor Andrew Fisher, Professor of Respiratory Transplant Medicine at Newcastle University, and Honorary Consultant Respiratory and Transplant Physician at The Newcastle upon Tyne Hospitals NHS Foundation Trust's Institute of Transplantation. The objective of his project is to perform an in depth mechanistic assessment of Extracorporeal Photopheresis (ECP) treatment in patients suffering from Chronic lung Allograft Dysfunction (CLAD).

Full details are available on our press release page.

Copy the link to share with the HCP by clicking on the button below

 
THANK YOU FOR YOUR MESSAGE
We will take care of your request and get in contact with you soon
 
THANK YOU FOR YOUR APPLICATION
We can confirm we have received your submission.
 
AUTHORISATION

The Therakos e-learning platform wants to access the following information:

Your basic public profile
Your public email address

Please click the below button to authorise it

WELCOME TO THERAKOS.EU MY AREA
Forgot your password? Click Here
Not yet registered?
WELCOME TO THERAKOS.EU MY AREA
Forgot your password?